Publications by authors named "P Chetchotisakd"
Article Synopsis
- Adult-onset immunodeficiency (AOID) is linked to anti-IFN-γ autoantibodies (auAbs), which may increase susceptibility to disseminated nontuberculous mycobacterial (dNTM) infections, alongside other molecular factors.
- A study involving dNTM patients assessed plasma anti-IFN-γ auAb levels through ELISA and whole-blood RNA sequencing, showing significantly higher auAb levels in active cases compared to inactive patients and healthy controls.
- The research found that active infection was marked by over-expressed inflammatory pathways, under-expressed type-2 immunity pathways, and elevated plasma IL-8 levels, suggesting IL-8 could potentially serve as a key mediator in
Background: Lenacapavir is a long-acting HIV-1 capsid inhibitor for treatment of HIV-1 infection. We evaluated the efficacy and safety of lenacapavir in combination with an investigator-selected optimized background regimen (OBR) after 104 weeks in adults with multidrug-resistant HIV-1.
Methods: This ongoing, international, Phase 2/3 trial at 42 sites included 72 adults living with multidrug-resistant HIV-1.
Melioidosis caused by Burkholderia pseudomallei (Bp) is a public health threat. Genomic-epidemiology research on this deadly disease is scarce. We investigated whole-genome sequences of Bp isolates in relation to environmental source and drug susceptibility.
View Article and Find Full Text PDFArticle Synopsis
- Melioidosis, caused by Burkholderia pseudomallei, triggers strong immune responses, prompting researchers to investigate two genetic variants (rs76600635 and rs5744168) previously linked to mortality in smaller studies.
- In a large study of 1,338 patients across nine hospitals in northeastern Thailand, neither genetic variant showed a significant association with bacteremia or 28-day mortality when analyzed.
- The findings suggest that these specific genetic variants do not influence the outcomes of melioidosis infections, contrasting with earlier single-center research.
Background: Ventilator-associated pneumonia (VAP) is associated with increased mortality, prolonged hospitalisation, excessive antibiotic use and, consequently, increased antimicrobial resistance. In this phase 4, randomised trial, we aimed to establish whether a pragmatic, individualised, short-course antibiotic treatment strategy for VAP was non-inferior to usual care.
Methods: We did an individually randomised, open-label, hierarchical non-inferiority-superiority trial in 39 intensive care units in six hospitals in Nepal, Singapore, and Thailand.